Maxion Therapeutics doubles R&D space at Unity Campus after £58 million Series A fundraise
Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, today announces has more than doubled its footprint at Unity Campus.
Following a successful £58 million ($72 million) Series A funding round earlier this year, Maxion has signed a new lease for Suite 5 at The Works building, securing nearly 9,000 sq ft of additional transformative laboratory and office space at Unity Campus to support the next stage of its growth journey.
The new space will enable Maxion, which first moved to Unity Campus in 2023, to continue scaling its research and development activities from a single, cohesive location, as it works towards its ultimate goal of improving the quality of life of patients with debilitating diseases.
Howard Group worked closely with Maxion to create a tailored real estate solution, aligning the new lease for Suite 5 with Maxion’s existing lease on Suite 4 (7,644 sq ft). This synchronisation offers important operational benefits and avoids unnecessary disruption to Maxion’s critical R&D work at Unity Campus.
The expansion takes Maxion’s total space at Unity Campus to over 16,000 sq ft.
Founded in 2019, Maxion Therapeutics leverages revolutionary KnotBody® technology to develop antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease. The Company’s recent landmark fundraising – one of the largest European private biotech financings since the beginning of 2024 – highlights the significant potential of the technology and development pipeline.
Arndt Schottelius, MD PhD, Maxion’s Chief Executive Officer, said:
Katherine Friend, Director – Investment and Asset Management, Howard Group, added:
For more information visit www.unitycampus.co.uk.
For more information, please contact:
Contact
ICR Healthcare
Mary-Jane Elliott / Ashley Tapp / Kate Hall
E-mail: MaxionTherapeutics@icrinc.com
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease. The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors. For more information, please visit:
https://www.maxiontherapeutics.com/
About Howard Group
Established in 1935 and with headquarters in the centre of Cambridge, Howard Group is a leading regional property investor and developer with a property investment portfolio in excess of £250m, made up of 24 properties, 1 million sq ft of occupied space and with nearly 100 tenants. The Group is also a collaborative and patient investment partner, supporting the next generation of entrepreneurs developing meaningful, knowledge-intensive businesses.
Howard Group invests in and develops high-quality and innovative places that have a positive long-term impact on the environment and the people in and around them. Whether it’s a state-of-the-art student accommodation scheme, a campus environment specifically tailored to support Cambridge’s burgeoning life science and innovation sectors or an industrial hub positioned within one of the most exciting regeneration and growth areas in London, the Group’s objective is to make sure these places meet the needs of those who interact with them, both now and into the future, leaving a lasting legacy for generations to come.
Find out more: www.howard-ventures.com
